341 229

Cited 35 times in

Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy

DC FieldValueLanguage
dc.contributor.author성진실-
dc.date.accessioned2014-12-18T09:52:42Z-
dc.date.available2014-12-18T09:52:42Z-
dc.date.issued2013-
dc.identifier.issn0027-8874-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/88998-
dc.description.abstractThe first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute on August 8-9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This workshop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and expected challenges in the development of molecularly targeted agents in combination with radiation therapy.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntineoplastic Agents/administration & dosage-
dc.subject.MESHAntineoplastic Agents/adverse effects-
dc.subject.MESHAntineoplastic Agents/pharmacology*-
dc.subject.MESHBiomarkers, Tumor/analysis*-
dc.subject.MESHBrain Neoplasms/radiotherapy-
dc.subject.MESHBrain Neoplasms/secondary-
dc.subject.MESHBreast Neoplasms/pathology-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHClinical Trials, Phase I as Topic-
dc.subject.MESHCongresses as Topic-
dc.subject.MESHCranial Irradiation-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMolecular Targeted Therapy/methods*-
dc.subject.MESHNational Cancer Institute (U.S.)-
dc.subject.MESHNeoplasms/chemistry-
dc.subject.MESHNeoplasms/drug therapy*-
dc.subject.MESHNeoplasms/pathology-
dc.subject.MESHNeoplasms/radiotherapy*-
dc.subject.MESHPrecision Medicine/trends*-
dc.subject.MESHRadiation-Sensitizing Agents/therapeutic use-
dc.subject.MESHRadiotherapy, Adjuvant-
dc.subject.MESHResearch Design-
dc.subject.MESHResearch Support as Topic-
dc.subject.MESHSeverity of Illness Index-
dc.subject.MESHUnited States-
dc.titleOpportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학)-
dc.contributor.googleauthorSteven H. Lin-
dc.contributor.googleauthorThomas J. George-
dc.contributor.googleauthorEdgar Ben-Josef-
dc.contributor.googleauthorJeffrey Bradley-
dc.contributor.googleauthorKevin S. Choe-
dc.contributor.googleauthorMartin J. Edelman-
dc.contributor.googleauthorChandan Guha-
dc.contributor.googleauthorSunil Krishnan-
dc.contributor.googleauthorTheodore S. Lawrence-
dc.contributor.googleauthorQuynh-Thu Le-
dc.contributor.googleauthorBo Lu-
dc.contributor.googleauthorMinesh Mehta-
dc.contributor.googleauthorDavid Peereboom-
dc.contributor.googleauthorJann Sarkaria-
dc.contributor.googleauthorJinsil Seong-
dc.contributor.googleauthorDian Wang-
dc.contributor.googleauthorMeng X. Welliver-
dc.contributor.googleauthorC. Norman Coleman-
dc.contributor.googleauthorBhadrasain Vikram-
dc.contributor.googleauthorStephen Yoo-
dc.contributor.googleauthorChristine H. Chung-
dc.identifier.doi10.1093/jnci/djt055-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01956-
dc.relation.journalcodeJ01896-
dc.identifier.eissn1460-2105-
dc.identifier.pmid23503600-
dc.subject.keywordAntineoplastic Agents/administration & dosage-
dc.subject.keywordAntineoplastic Agents/adverse effects-
dc.subject.keywordAntineoplastic Agents/pharmacology*-
dc.subject.keywordBiomarkers, Tumor/analysis*-
dc.subject.keywordBrain Neoplasms/radiotherapy-
dc.subject.keywordBrain Neoplasms/secondary-
dc.subject.keywordBreast Neoplasms/pathology-
dc.subject.keywordChemotherapy, Adjuvant-
dc.subject.keywordClinical Trials, Phase I as Topic-
dc.subject.keywordCongresses as Topic-
dc.subject.keywordCranial Irradiation-
dc.subject.keywordHumans-
dc.subject.keywordKaplan-Meier Estimate-
dc.subject.keywordMolecular Targeted Therapy/methods*-
dc.subject.keywordNational Cancer Institute (U.S.)-
dc.subject.keywordNeoplasms/chemistry-
dc.subject.keywordNeoplasms/drug therapy*-
dc.subject.keywordNeoplasms/pathology-
dc.subject.keywordNeoplasms/radiotherapy*-
dc.subject.keywordPrecision Medicine/trends*-
dc.subject.keywordRadiation-Sensitizing Agents/therapeutic use-
dc.subject.keywordRadiotherapy, Adjuvant-
dc.subject.keywordResearch Design-
dc.subject.keywordResearch Support as Topic-
dc.subject.keywordSeverity of Illness Index-
dc.subject.keywordUnited States-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.rights.accessRightsfree-
dc.citation.volume105-
dc.citation.number10-
dc.citation.startPage686-
dc.citation.endPage693-
dc.identifier.bibliographicCitationJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol.105(10) : 686-693, 2013-
dc.identifier.rimsid33731-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.